argenx Meets Primary Endpoint in Phase 3 ALKIVIA Trial for Autoimmune Myositis

1. 1argenx (ARGX) announces VYVGART Hytrulo met the primary endpoint in the Phase 3 ALKIVIA trial in adult patients with autoimmune myositis
2. 2Mean TIS at 52 weeks was 47.95 vs 32.56 for placebo, a 15.4-point advantage (p=0.0011) in the integrated primary analysis of IMNM and DM
3. 3IMNM, a subtype with no approved therapy, showed first significant Phase 3 improvement; DM showed clinically meaningful improvement but missed statistical significance at p=0.1093

Source InvestorsHub +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →